WI
Windlas Biotech Ltd (WINDLAS)
₹1,039.10
Mkt cap
₹2,289 Cr
P/E ratio
34.50
P/B
3.78
Div yield
0.57%
ROE
12.20%
ROCE
15.90%
EPS (TTM)
₹30.12
Book value
₹275
52W range
697–1,182
Sector
Healthcare
Price history
Previous close
Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics. [1]
NSE WINDLASBSE 543329
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−12.08% from high₹1,039
₹697+49.00% from low₹1,182
Current
₹1,039.10
Prev close
₹1,017.20
Day
+2.15%
Price performance
1D
+2.15%
1W
−5.75%
1M
−7.81%
3M
+21.68%
6M
+35.92%
1Y
+12.62%
YTD
+31.72%
Financials
Revenue, profit & margin
P/E ratio
34.5×
WINDLAS is 0% below the sector median of 34.6×
WINDLAS34.5×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 145 | 153 | 162 | 171 | 175 | 187 | 195 | 203 | 210 | 222 | 233 | 238 | 248 | |
| Expenses | 128 | 134 | 142 | 149 | 154 | 164 | 170 | 177 | 184 | 194 | 209 | 213 | 221 | |
| Operating Profit | 17 | 19 | 20 | 22 | 21 | 23 | 25 | 26 | 27 | 29 | 24 | 25 | 27 | |
| OPM % | 12% | 12% | 13% | 13% | 12% | 12% | 13% | 13% | 13% | 13% | 10% | 11% | 11% | |
| Other Income | 3 | 3 | 3 | 4 | 4 | 5 | 4 | 5 | 5 | 4 | 5 | 4 | 5 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | |
| Depreciation | 3 | 3 | 3 | 4 | 6 | 6 | 7 | 8 | 7 | 8 | 8 | 8 | 7 | |
| Profit before tax | 16 | 18 | 20 | 23 | 18 | 20 | 20 | 21 | 23 | 24 | 20 | 20 | 23 | |
| Tax % | 26% | 23% | 24% | 25% | 26% | 23% | 24% | 22% | 24% | 25% | 25% | 21% | 23% | |
| Net Profit | 12 | 14 | 15 | 17 | 13 | 16 | 15 | 16 | 18 | 18 | 15 | 16 | 18 | |
| EPS in Rs | 5.80 | 6.75 | 7.26 | 8.15 | 6.45 | 7.49 | 7.29 | 7.77 | 8.43 | 8.45 | 7.09 | 7.59 | 8.55 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +12.32% · closed higher next day 1 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 10 Aug '26◦ |
| Earnings day | +12.32% |
| +1 day | +6.56% |
| +5 days | +9.33% |
| +15 days | +20.09% |
| +30 days | +28.32% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202663.31%Promoter
Promoters63.31%1.41
FIIs2.04%1.44
DIIs9.84%1.96
Public24.80%0.89
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Windlas Biotech | ₹1,109.45 | 34.47 | 2,289 | 0.57% | 18 | −0.11% | 248 | +18.09% | 15.90% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports6
Concall transcripts51
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptAug 2024PPTAug 2024RECAug 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 1 Sep - Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (LODR), Regulations 2015Announcement under Regulation 30 (LODR)-Earnings Call Transcript 14 AugIntimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Recording Of Conference Call 11 Aug - Audio recording of June 30, 2026 results conference call uploaded; transcript to follow.Announcement under Regulation 30 (LODR)-Press Release / Media Release 10 Aug - Windlas Biotech reported Q1 FY27 revenue of Rs 248 crore, PAT Rs 25 crore, and completed a Rs 47 crore buyback.Announcement under Regulation 30 (LODR)-Investor Presentation 10 Aug